• News
  • BioTech

Zogenix objects to new Massachusetts restrictions

A San Diego company that makes the new prescription painkiller Zohydro says it is disappointed with Massachusetts Gov. Deval Patrick's decision to impose new restrictions on the drug after a federal judge said his attempt to ban it outright was unconstitutional.

The new requirements, announced by Patrick on Tuesday, include the doctor's completion of a risk assessment and a “pain management treatment agreement” with the patient before prescribing drugs like Zohydro.

Drugmaker Zogenix (Nasdaq: ZGNX) said in a statement Wednesday that with the new rules, the governor is continuing to unfairly single out the new drug even as the company maintains the medication is no riskier than other opioids currently on the market.

“Imposing restrictions on one specific treatment without developing a full understanding of the facts and the causes of the problem does not serve the public interest,” the statement said.

The company also said Patrick has not accepted its offer to discuss the issue and to work together to address the needs of patients and the problem of illegal drug use.

Neither Patrick nor the state public health commissioner immediately responded to requests for comment.

A federal judge last week blocked the state from enforcing an outright ban, which the governor issued through an executive order in March in response to a surge of drug overdoses and deaths in the state.

Zohydro contains up to five times the amount of narcotic hydrocodone previously available in pills, and some health officials say the drug can be easily crushed and then inhaled or injected, making it susceptible to abuse.

User Response
0 UserComments

Zogenix Inc.

Company Website

12400 High Bluff Dr. Ste., 650
San Diego, CA 92130

Zogenix Inc. Executive(s):

Roger Hawley

  • Chief Executive Officer

Stephen Farr

  • President

Ann Rhoads

  • Chief Financial Officer